Enlivex Therapeutics (ENLV) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.
The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.
Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.
Shares of Enlivex Therapeutics were down 1.6% in recent trading.
Price: 1.23, Change: -0.02, Percent Change: -1.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。